All Updates

All Updates

icon
Filter
FDA approval
Blueprint Medicines receives FDA approval for AVYAKIT
Precision Medicine
May 22, 2023
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Precision Medicine

Precision Medicine

May 22, 2023

Blueprint Medicines receives FDA approval for AVYAKIT

FDA approval

  • Blueprint Medicines, a global commercial-stage precision medicine drug developer, has received FDA approval for AYVAKIT as a treatment for adults with indolent systemic mastocytosis (ISM). ISM is a rare hematologic disorder that causes debilitating symptoms across multiple organ systems. The majority of systemic mastocytosis (SM) cases are classified as ISM.

  • AYVAKIT is the first FDA-approved treatment for ISM, and it inhibits the primary underlying driver of the disease. It is a precision therapy that targets the KIT D816V mutation, which is responsible for driving SM. It has been approved by the FDA for the treatment of advanced SM since June 2021. The medicine has shown significant clinical improvements in terms of symptoms and mast cell burden reduction in a large clinical trial.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.